OncoPharm

John Bossaer
undefined
Nov 19, 2026 • 16min

Prostate Cancer Screening, DasaHit, & CHARGE Index

Updated prostate cancer screening guidance takes center stage, including PSA timing for average- and high-risk men and concerns about overtreatment. The DASAHIT trial explores weekday-only dasatinib dosing in chronic-phase CML. Plus, the CHARGE index emerges as a powerful prognostic tool for multiple myeloma treated with bispecific T-cell therapies.
undefined
Nov 12, 2026 • 15min

Updated CRS & ICANS Grading plus ZINCLO HAND

Explore updated grading for CRS and ICANS, plus newly recognized toxicities after CAR-T and bispecific therapies. The ZINCLO-HAND trial tests oral zinc and topical clobetasol for regorafenib-related hand-foot skin reactions. Also covered: accelerated approval of amivantamab-hyaluronidase for recurrent metastatic p16-negative head and neck cancer, and pimicotinib for tenosynovial giant cell tumor.
undefined
Nov 5, 2026 • 17min

PARPi's & ARPi's

PARP inhibitors meet androgen receptor pathway inhibitors in the frontline treatment of advanced prostate cancer. The discussion explores BRCA2-driven benefit, evidence from MAGNITUDE, PROpel, and TALAPRO-3, HRR mutation subgroups, and the practical choice between abiraterone and enzalutamide. Also covered: methylphenidate for fatigue in hematologic cancers and the role of exercise.
undefined
Oct 29, 2026 • 24min

ESMO 26

Explore major oncology updates from ESMO 2026, including tarlatamab’s survival gains in small-cell lung cancer, the withdrawal of lurbinectedin’s approval, and a personalized mRNA vaccine’s promise in melanoma. Also covered: darolutamide after prostatectomy, a bladder cancer “sandwich” strategy, narrowed pembrolizumab eligibility, and unexpected mortality with venetoclax in double-hit lymphoma.
undefined
Oct 22, 2026 • 11min

Dostarlimab's Journey in MMRd Rectal Cancer

A look back at dostarlimab’s path to accelerated approval in mismatch repair-deficient or MSI-high locally advanced rectal cancer. The discussion covers the striking early complete responses, expanded multicenter results, the ACER-1 study design, response rates, recurrence monitoring, and lingering safety questions. Also featured: sunvozertinib’s commercial launch for EGFR exon 20 insertion-mutated lung cancer.
undefined
Oct 15, 2026 • 16min

Blinatumomab & Ponatinib for ALL

A randomized trial puts blinatumomab plus ponatinib in the spotlight for Philadelphia-positive adult ALL, with comparisons to earlier induction experience, transplant strategies, and dosing approaches. The discussion also explores expanded oncology indications: atezolizumab with FOLFOX for adjuvant dMMR colon cancer and nogapendekin alfa inbakicept with BCG for high-grade bladder cancer.
undefined
Oct 8, 2026 • 14min

HER2 Climb 05

Tucatinib earns expanded first-line approval for HER2-positive metastatic breast cancer, prompting a look at HER2-CLIMB05, progression-free survival, toxicity, cost, and comparisons with DESTINY-Breast09. Pirtobrutinib gains an initial CLL/SLL indication. Australia takes a bold site-agnostic approach to funding nivolumab-ipilimumab and pembrolizumab.
undefined
8 snips
Oct 1, 2026 • 16min

Lirafugratinib + LITESPARK011

Lirafugratinib’s approval brings a fresh look at FGFR inhibitors for FGFR2-altered cholangiocarcinoma, including phosphate, eye, skin, and drug-interaction concerns. The discussion then turns to LITESPARK-011, comparing lenvatinib plus belzutifan with cabozantinib in advanced clear-cell kidney cancer, with attention to response rates, toxicity, quality of life, and still-immature survival data.
undefined
Sep 24, 2026 • 10min

PI3K Pathway Hyperglycemia

Drugs that inhibit signaling via the PI3K pathway (e.g. alpelisib, capivasertib) can cause hyperglycemia. The mechanism of this ADR as well as the implications of which anti-diabetes medications are used in response is discussed. Review article: https://doi.org/10.1177/15347354211073163 Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm
undefined
Sep 17, 2026 • 14min

Neutropenic Diets & Lung Cancer Updates

This week's podcast discusses a recent meta-analysis on the benefit of a "neutropenic diet" in patients on treatment for cancer. Link: https://doi.org/10.1200/OP-26-00405 The 2026 World Conference on Lung Cancer just wrapped up. We run through the findings of the most notable trials presented at WCLC. Download the Learning Oncology Companion:https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app